Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures

Not Applicable

Not yet recruiting

• Conditions: Metastatic Liver Cancer; Hepatocellular Carcinoma
• Interventions: Device: BioTraceIO 360

• Registration Number: NCT05582018
• Lead Sponsor: Techsomed Medical Technologies LTD

Brief Summary

Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures

Multi-center (up to 5 investigational sites) prospective single-arm clinical investigation.

Sample size - 30 subjects.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-10
• Study First Submitted: 2022-10-12
• Study First Submitted QC: 2022-10-12
• Study First Posted: 2022-10-17
• Last Update Submitted: 2023-04-16
• Last Update Posted: 2023-04-18
• Study Start: 2023-06
• Primary Completion: 2023-12
• Study Completion: 2023-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Scheduled and indicated for standard-of-care liver tumor ablation for either hepatocellular carcinoma (HCC) or metastatic liver tumor(s) microwave (MW) energy.
• Patient must have at least one prior CT or CECT scan (up to 6 months before enrollment).
• Tumor must be visualized on at least one diagnostic imaging modality (MRI or contrast-enhanced CT).
• Single tumor, or multiple tumors only if the distance between the ablated tumor and all other tumors allows for distinct separation between the necrotic zones.
• Distance between the tumor and the edge of any previous necrotic zones allows for distinct separation between the necrotic zones.
• At least 21 years of age.
• Able and willing to give informed consent.

Additional inclusion criteria for subgroup:

• Single ablation, using a single ablation needle, per tumor.

Exclusion Criteria

• Planned ablation includes adjunctive means other than MW energy (e.g., ethanol, hepatic artery embolization, etc.).
• Planned ablation includes the use of more than two ablation needles, per tumor
• Ablation area cannot be visualized and monitored continuously using ultrasound throughout the entire ablation procedure.
• Pregnant or breastfeeding.
• Patient judged unsuitable for study participation by the physician for any other reason.
• Currently participating in another clinical trial of an unapproved investigational device or drug that has not concluded the follow-up period.
• Unable or unwilling to give informed consent.

Additional exclusion criteria for subgroup:

• Liver tumor that cannot be ablated with a single ablation needle, according to the investigator's clinical opinion.
• Planned ablation includes repositioning and/or overlapping ablations using a single ablation needle.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BioTrace	BioTraceIO 360	Use of the BioTraceIO 360 device for planning, monitoring and assessment of liver tissue ablations

Primary Outcome Measures

Name	Time	Method
Effectiveness	1 year	The percentage of patients for whom (1) probe(s) position suggestion provided by the BioTraceIO 360 device is in agreement with the planned probe(s) position, as determined by the physician without the use of the device, or (2) clinically feasible probe(s) positioning suggestion was provided by the BioTraceIO 360 device, in addition to the planned probe(s) position by the physician without the use of the device.
Safety	1 year	Incidence and severity of device-related adverse

Secondary Outcome Measures

Name	Time	Method
Planning Module	1 year	The proportion of subjects in whom the physician has made changes and/or reported increased confidence to the planned ablation procedure after using the BioTraceIO 360 Planning Module compared to without using it.
Monitoring Module	1 year	A non-validated qualitative assessment for the physician regarding confidence during the procedure without and with the use of BioTraceIO 360 Monitoring Module if they could have made clinical decisions based on the use of the device.
Assessment Module (1)	1 year	A non-validated qualitative assessment on whether there were subjects, in whom the physician indicated that they would have changed the procedure and/or follow-up decision if they could have made clinical decisions based on the visualization of the tumor compared to the necrosis, using the BioTraceIO 360 Assessment Module at the end of the procedure.